(December 2, 2016, 1:09 PM EST) -- WASHINGTON, D.C. — Apotex Inc. and Apotex Corp. (collectively, Apotex) argue in a Nov. 21 reply brief to the U.S. Supreme Court that biotechnology companies that lost an underlying patent case unfairly get “to reap another six months of monopoly profits beyond the statutory 12-year period on a product that could help more people while saving the healthcare system billions of dollars in unnecessary expenditures” (Apotex Inc. and Apotex Corp. v. Amgen Inc. and Amgen Manufacturing Ltd., No. 16-332, U.S. Sup.)....